Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defibrotide in Human Endotoxemia Model
NCT02876601Phase 4Completed
- Start
- Apr 2017
- Primary completion
- Feb 2018
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of defibrotide in hepatic veno-occlusive disease (HVOD) (4 cohorts). Primary endpoint: Prothrombin Fragments f1+2 at 24 hours. Started Apr 2017; status: completed.
02
Drugs
defibrotide
03
Conditions
hepatic veno-occlusive disease (HVOD)
Beyond the preview
Go deeper on NCT02876601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02876601.